IOMEDICO AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Registry Platform Ovarian and Endometrial Cancer

Recruiting

Conditions: Endometrial Cancer
Ovarian Cancer
Ovary Neoplasm
Endometrial Neoplasms
Carcinoma, Ovarian
Carcinoma
Neoplasm, Ovarian

Interventions: Other: Physician's choice according to patient's needs.

First Posted Date: 2021-11-22

Last Posted Date: 2024-10-15

Lead Sponsor: iOMEDICO AG

Target Recruit Count: 1375

Registration Number: NCT05129969

Locations: 🇩🇪
Multiple sites all over Germany, Multiple Locations, Germany

Registry Platform Colorectal Cancer

Active, not recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Other: Physician's choice according to patient's needs.

First Posted Date: 2021-04-30

Last Posted Date: 2024-03-12

Lead Sponsor: iOMEDICO AG

Target Recruit Count: 500

Registration Number: NCT04867525

Locations: 🇩🇪
Multiple sites all over germany, Multiple Locations, Germany

Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion

Active, not recruiting

Conditions: NTRK Family Gene Mutation

First Posted Date: 2020-09-22

Last Posted Date: 2024-03-01

Lead Sponsor: iOMEDICO AG

Target Recruit Count: 88

Registration Number: NCT04557813

Locations: 🇩🇪
Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany
🇩🇪
Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany
🇩🇪
Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Germany

and more 20 locations

Liver Cancer Registry Platform

Recruiting

Conditions: Hepatocellular Carcinoma (HCC)
Cholangiocarcinoma

Interventions: Other: Physician's choice according to patient's needs.

First Posted Date: 2020-08-12

Last Posted Date: 2024-10-14

Lead Sponsor: iOMEDICO AG

Target Recruit Count: 1000

Registration Number: NCT04510740

Locations: 🇩🇪
Multiple sites all over germany, Multiple Locations, Germany

Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed

Conditions: Advanced Solid Tumors or Hematologic Malignancies

First Posted Date: 2020-05-15

Last Posted Date: 2023-08-14

Lead Sponsor: iOMEDICO AG

Target Recruit Count: 499

Registration Number: NCT04389541

Locations: 🇩🇪
Hämatologisch-Onkologische Praxis Eppendorf (HOPE), Hamburg, Germany
🇩🇪
Hämatologisch-Onkologische Praxis Altona (HOPA), Hamburg, Germany
🇩🇪
Klinikum Darmstadt, Onkologisches Studienzentrum, Darmstadt, Germany

and more 91 locations

Registry Platform Gastric/Esophageal Cancer (SAPHIR)

Recruiting

Conditions: Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Esophageal Squamous Cell Carcinoma
Gastric Adenocarcinoma

Interventions: Other: Routine care as per site standard

First Posted Date: 2020-03-02

Last Posted Date: 2024-08-09

Lead Sponsor: iOMEDICO AG

Target Recruit Count: 900

Registration Number: NCT04290806

Locations: 🇩🇪
Multiple sites, Gemany, Multiple Locations, Germany

Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy

Completed

Conditions: Stage IV Non-small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer
Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC

Interventions: Other: eHealth system support for symptom management via CANKADO

First Posted Date: 2019-04-11

Last Posted Date: 2021-10-05

Lead Sponsor: iOMEDICO AG

Target Recruit Count: 154

Registration Number: NCT03911219

Locations: 🇩🇪
Gemeinschaftspraxis Dr. Heinrich, Prof. Dr. Bangerter, Augsburg, Germany
🇩🇪
Hämato- Onkologische Praxis im Medicum, Bremen, Germany
🇩🇪
MVZ des Städtischen Klinikums Dessau GmbH, Dessau, Germany

and more 85 locations

A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Phase 3

Withdrawn

Conditions: Advanced Breast Cancer
HER2-positive Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Pertuzumab
Drug: Vinorelbine
Drug: Docetaxel

First Posted Date: 2019-01-22

Last Posted Date: 2019-11-26

Lead Sponsor: iOMEDICO AG

Registration Number: NCT03811418

Locations: 🇩🇪
iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany

Patient Preference for Pegfilgrastim (Neulasta®) Application Forms

Not Applicable

Completed

Conditions: Non Hodgkin Lymphoma
Breast Cancer

Interventions: Device: On-body injector
Device: Pre-filled syringe

First Posted Date: 2018-08-08

Last Posted Date: 2019-12-17

Lead Sponsor: iOMEDICO AG

Target Recruit Count: 404

Registration Number: NCT03619993

Locations: 🇩🇪
Research Site, Würselen, Germany

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

Phase 3

Completed

Conditions: Breast Cancer
Hormone Receptor Positive Tumor
HER 2 Negative Breast Cancer

Interventions: Combination Product: Ribociclib and aromatase inhibitor or fulvestrant
Combination Product: Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab

First Posted Date: 2018-03-12

Last Posted Date: 2023-01-19

Lead Sponsor: iOMEDICO AG

Target Recruit Count: 41

Registration Number: NCT03462251

Locations: 🇩🇪
Klinikum Mittelbaden Baden-Baden Balg, Baden-Baden, Germany
🇩🇪
Uniklinik RWTH Aachen, Gynäkologie und Geburtsmedizin, Aachen, Germany
🇩🇪
Gemeinschaftspraxis für Hämatologie und Onkologie, Westerstede, Germany

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy